1JR3, Department of Anatomy, IMS, BHU, Varanasi
2Professor, Department of Anatomy, IMS, BHU, Varanasi
*Corresponding author: Dr Nidhi Sunhare, JR3, Department of Anatomy, IMS, BHU, Varanasi E-mail: nidhisunhare@gmail.com
Online published on 5 May, 2018.
Lamivudine is a nucleoside analogue reverse transcriptase inhibitor used for treatment of hepatitis B and HIV virus infection in pregnant females and to prevent maternal to child transmission. The present study is aimed to investigate the teratogenicity of Lamivudine in growing embryo in swiss albino mice.
Lamivudine was given to pregnant Swiss Albino mice by oral gavage in doses of 18mg/kg body weight and 30mg/kg body weight from 6–15th day of gestation. The control mice were fed distilled water by the same route on the same gestational days. The pregnant mice were sacrificed on 18th day of gestation by cervical dislocation. The foetuses and placentae were observed for any gross malformation.
On the gross examination it was observed that there was a significant reduction in the weight of foetuses and growth retardation. Also haemorrhagic patches were observed on the body. Reduction in weight and diameter of placenta size was not significant.
Lamivudine causes teratological changes in mice foetus and should be used judiciously in pregnant females.
Teratogenicity, hemorrhagic patches, growth retardation, reverse transcriptase
